Feb. 13 at 6:21 PM
$EVMN 02/12/2026 - 06:30 PM
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)-- Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is
$27.88. Evommune anticipates the gross proceeds from the private placement to be approximately
$125 million, before deducting any transaction-related expenses. The private placement is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions.
